Business Context and Reporting Period
Myomo, Inc. filed this Form 8-K on February 7, 2019, to announce the commencement of a common stock offering. The filing provides preliminary, unaudited financial data for the three months and year ended December 31, 2018, noting that final financial closing procedures were not yet complete at the time of filing.
Key Financial Metrics
| Metric | Value | Period/Date |
|---|---|---|
| Cash, Cash Equivalents, and Short-Term Investments | $6.5 million | December 31, 2018 |
| Total Revenues | $0.9 million | Three months ended Dec 31, 2018 |
| Total Revenues | $2.4 million | Year ended Dec 31, 2018 |
| MyoPro Units in Reimbursement Process | 306 units | As of December 31, 2018 |
The filing does not provide specific figures for net profit, operating margins, debt levels, or cash flow from operations. Profitability and margin data are not disclosed in this text.
Material Changes
- Liquidity Decline: Cash, cash equivalents, and short-term investments decreased to approximately $6.5 million as of December 31, 2018, compared to $13.0 million at December 31, 2017, and $9.1 million at September 30, 2018.
- Reimbursement Pipeline: The company added 139 MyoPro units to the reimbursement process during the fourth quarter of 2018, bringing the total to 306 units as of year-end.
Outlook, Risks, and Management Commentary
Management emphasized that the financial data presented is preliminary and subject to change upon completion of the year-end review process. There is no assurance that final results will not differ materially from these estimates. The company stated that complete quarterly results will be announced during the full-year financial results conference call and included in the Annual Report on Form 10-K. Independent auditors have not reviewed or expressed an opinion on this preliminary data.
Investor Verification Checklist
- Verify the final audited cash position and revenue figures in the upcoming Form 10-K for the year ended December 31, 2018.
- Confirm the status of the 306 MyoPro units in the reimbursement process and their impact on future revenue recognition.
- Review the terms and proceeds of the common stock offering announced on February 7, 2019.
- Assess the reasons for the significant decline in cash reserves from $13.0 million in 2017 to $6.5 million in 2018.